Tetraphase Pharma (TTPH) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Needham & Company Raises Price Target on Tetraphase Pharma (TTPH) to $56 Ahead of Phase 3 cUTI Results
August 6, 2015 8:56 AM EDTNeedham & Company reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ: TTPH), and raised the price target to $56.00 (from $46.00), ahead of Phase 3 cUTI results. Analyst Alan Carr believes that superiority is probable given encouraging data from the lead-in portion of the trial. TTPH reiterated its... More
